A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors JOURNAL OF HEMATOLOGY & ONCOLOGY de Vos, S., Forero-Torres, A., Ansell, S. M., Kahl, B., Cheson, B. D., Bartlett, N. L., Furman, R. R., Winter, J. N., Kaplan, H., Timmerman, J., Whiting, N. C., Drachman, J. G., Advani, R. 2014; 7

View details for DOI 10.1186/1756-8722-7-44

View details for Web of Science ID 000338587000001